|
| 36331676 | Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. | Invest New Drugs | 2023 |
| 37606183 | Integrated variant allele frequency analysis pipeline and R package: easyVAF. | Mol Carcinog | 2023 |
| 37389416 | The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma. | J Natl Cancer Inst | 2023 |
| 36963390 | Generation of functional thymic organoids from human pluripotent stem cells. | Stem Cell Reports | 2023 |
| 36847625 | Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer. | Drugs Today (Barc) | 2023 |
| 36577897 | Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. | Nat Cancer | 2023 |
| 36867316 | Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. | Invest New Drugs | 2023 |
| 34331993 | Generation of functional human thymic cells from induced pluripotent stem cells. | J Allergy Clin Immunol | 2022 |
| 35731258 | A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. | Cancer Chemother Pharmacol | 2022 |
| 35417043 | Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. | Mol Carcinog | 2022 |
| 36434392 | A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. | Nat Cancer | 2022 |
| 35940825 | Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. | J Immunother Cancer | 2022 |
| 35904620 | A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies. | Cancer Chemother Pharmacol | 2022 |
| 35276673 | NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. | J Natl Compr Canc Netw | 2022 |
| 34862248 | Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. | Clin Cancer Res | 2022 |
| 34800678 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer<sup>â¿¿</sup>. | Ann Oncol | 2022 |
| 33414263 | Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. | J Immunother Cancer | 2021 |
| 33594387 | Capmatinib for non-small cell lung cancer. | Drugs Today (Barc) | 2021 |
| 33634324 | A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. | Cancer Chemother Pharmacol | 2021 |
| 34821881 | Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. | Drugs Today (Barc) | 2021 |
| 34433873 | Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. | Commun Biol | 2021 |
| 34546978 | Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. | JCI Insight | 2021 |
| 33087417 | Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. | Mol Cancer Res | 2021 |
| 31227647 | Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). | Oncologist | 2020 |
| 31911553 | Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma. | Cancer Res | 2020 |
| 33025950 | Avapritinib for metastatic or unresectable gastrointestinal stromal tumors. | Drugs Today (Barc) | 2020 |
| 33025948 | Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma. | Drugs Today (Barc) | 2020 |
| 33037117 | Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. | J Immunother Cancer | 2020 |
| 32634781 | Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 32816856 | Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells. | Cancer Res | 2020 |
| 32309823 | Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. | Drugs Today (Barc) | 2020 |
| 32525136 | Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors. | Drugs Today (Barc) | 2020 |
| 32275343 | The humanized mouse: Emerging translational potential. | Mol Carcinog | 2020 |
| 30575147 | Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas. | Mol Carcinog | 2019 |
| 30229512 | A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. | Invest New Drugs | 2019 |
| 31586893 | Leading edge or tumor core: Intratumor cancer stem cell niches in oral cavity squamous cell carcinoma and their association with stem cell function. | Oral Oncol | 2019 |
| 31417185 | MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma. | Oncogene | 2019 |
| 30740608 | Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone. | Drugs Today (Barc) | 2019 |
| 30894369 | Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. | Cancer Res | 2019 |
| 30378175 | Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions. | Mol Carcinog | 2019 |
| 30576970 | Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with â¿¥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. | Eur J Cancer | 2019 |
| 28887726 | Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. | Ann Surg Oncol | 2018 |
| 30129680 | Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer. | Mol Carcinog | 2018 |
| 29931076 | Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. | JAMA Oncol | 2018 |
| 29848571 | Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers. | Clin Cancer Res | 2018 |
| 30084837 | Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. | Clin Cancer Res | 2018 |
| 29555661 | Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. | Clin Cancer Res | 2018 |
| 29752322 | NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. | J Natl Compr Canc Netw | 2018 |
| 29637937 | Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. | Drugs Today (Barc) | 2018 |
| 29771253 | Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. | Drugs Today (Barc) | 2018 |